• Biogen MS drug hit by EU safety restriction pharmaphorum
    July 11, 2017
    Biogen’s Zinbryta multiple sclerosis drug has suffered a serious setback after European regulators restricted its use because of liver safety concerns.
PharmaSources Customer Service